IRD.O (IRD.O) News
Follow IRD.O (IRD.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Opus Genetics Wins FDA Approval for Ryzumvi to Treat Presbyopia in Adults
Opus Genetics secured FDA clearance for Ryzumvi, phentolamine ophthalmic solution 0.75%, to treat presbyopia in adults, expanding its U.S. indications. Already reported Phase 3 VEGA-2 and VEGA-3 results met all primary a
REGULATION | Oct 16, 2026, 04:03 PM UTC
L
Opus Genetics' OPGx — BEST1 improves retinal sensitivity in 75% of evaluable patients in early — stage trial
Opus Genetics presented positive clinical results for its OPGx-LCA5 and OPGx-BEST1 gene therapies at Retina in Rio 2026. OPGx-LCA5 showed sustained vision improvements in adults through 24 months, with encouraging pediat
NEWS | Oct 15, 2026, 08:03 PM UTC
L
Opus Genetics presents at Chardan Annual Healthcare Conference
Opus Genetics management will present at the Chardan Annual Healthcare Conference on Oct. 20, 2026 at 10:00 a.m. ET. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intel
NEWS | Oct 13, 2026, 11:05 AM UTC